Business
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
Closing of additional $50 million tranche of $100 million equity private placement after achievement of clinical milestone for rondecabtagene autoleucelSmital Shah appointed Chief Financial and Business Officer SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced it has closed the sale
About this update from Lyell Immunopharma, Inc.
[{"type":"image","alt":"Lyell Immunopharma, Inc","displaySize":"","headline":null,"caption":"Lyell Immunopharma, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":222,"url":"https://media.zenfs.com/en/globenewswire.com/556ff8f6e9f697759b2abefc499d292d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gyyLnTdzLBmCtbGQjs4MFg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMxMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/556ff8f6e9f697759b2abefc499d292d","width":300,"height":222}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Closing of additional $50 million tranche of $100 million equity private placement after achievement of clinical milestone for rondecabtagene autoleucel","length":152,"tagName":"p"}]},{"val":[{"type":"text","content":"Smital Shah appointed Chief Financial and Business Officer","length":58,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":210,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced it has closed the sale of an additional $50 million of shares of its common stock to investors from its July 2025 equity private placement of up to $100 million, following achievement of a clinical milestone within its PiNACLE pivotal trial evaluating rondecabtagene autoleucel (ronde-cel) in patients with relapsed/refractory large B-cell lymphoma (LBCL) in the third- or later-line setting. The Company also announced the appointment of Smital Shah as its Chief Financial and Business Officer, effective March 9, 2026.","length":786,"tagName":"p"},{"type":"text","content":"“Smital’s deep expertise in navigating complex financial landscapes and her proven track record of strategic leadership in the biotechnology industry make her the ideal partner to guide Lyell’s financial strategy as we enter a transformative year of execution,” said Lynn Seely, M.D., President and CEO of Lyell. “The attainment of the second $50 million tranche of the private placement is evidence of Lyell’s continued advancement toward significant value inflection points. Smital’s insights will be invaluable in ensuring we remain well-capitalized and ope...